Correction to: EVI2B is a C/EBPα target gene required for granulocytic differentiation and functionality of hematopoietic progenitors.

Journal

Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445

Informations de publication

Date de publication:
Jan 2019
Historique:
pubmed: 12 7 2018
medline: 12 7 2018
entrez: 12 7 2018
Statut: ppublish

Résumé

Since publication of this article, the authors identified an error in the acknowledgments section. The original sentence in acknowledgments reads as follows.

Identifiants

DOI: 10.1038/s41418-018-0146-z PMID: 29991745 PMC: PMC6294764
pubmed: 29991745
doi: 10.1038/s41418-018-0146-z
pii: 10.1038/s41418-018-0146-z
pmc: PMC6294764
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

198

Commentaires et corrections

Type : ErratumFor

Auteurs

Polina Zjablovskaja (P)

Department of Hemato-Oncology, Institute of Molecular Genetics of the ASCR, Videnska 1083, Prague 142 20, Prague 4, Czech Republic.
Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague, University Hospital Motol, V Uvalu 84, Praha, 150 06, Czech Republic.

Miroslava Kardosova (M)

Department of Hemato-Oncology, Institute of Molecular Genetics of the ASCR, Videnska 1083, Prague 142 20, Prague 4, Czech Republic.

Petr Danek (P)

Department of Hemato-Oncology, Institute of Molecular Genetics of the ASCR, Videnska 1083, Prague 142 20, Prague 4, Czech Republic.

Pavla Angelisova (P)

Department of Molecular Immunology, Institute of Molecular Genetics of the ASCR, Videnska 1083, Prague, 142 20, Czech Republic.

Touati Benoukraf (T)

Cancer Science Institute, National University of Singapore, 14 Medical Drive, Singapore, 117599, Singapore.

Alexander A Wurm (AA)

Division of Hematology and Oncology, Leipzig University Hospital, Leipzig, Germany.

Tomas Kalina (T)

Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague, University Hospital Motol, V Uvalu 84, Praha, 150 06, Czech Republic.

Stephanie Sian (S)

Cancer Science Institute, National University of Singapore, 14 Medical Drive, Singapore, 117599, Singapore.

Martin Balastik (M)

Department of Molecular Neurobiology, Institute of Physiology of the ASCR, Videnska 1083, Prague, 142 20, Czech Republic.

Ruud Delwel (R)

Department of Hematology, Erasmus University Medical Center, Wytemaweg 80, Rotterdam, 3015 CN, The Netherlands.

Tomas Brdicka (T)

Department of Leukocyte Signalling, Institute of Molecular Genetics of the ASCR, Videnska 1083, Prague, 142 20, Czech Republic.

Daniel G Tenen (DG)

Cancer Science Institute, National University of Singapore, 14 Medical Drive, Singapore, 117599, Singapore.
Department Hematology/Oncology, Harvard Stem Cell Institute, Harvard Medical School, 3 Blackfan Circle, Boston, 02115, MA, USA.

Gerhard Behre (G)

Division of Hematology and Oncology, Leipzig University Hospital, Leipzig, Germany.

Fréderic Fiore (F)

Centre d'Immunophénomique, Aix Marseille Université, Inserm, CNRS, Marseille, F-13288, France.

Bernard Malissen (B)

Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université, Inserm, CNRS, Marseille, F-13288, France.

Vaclav Horejsi (V)

Department of Molecular Immunology, Institute of Molecular Genetics of the ASCR, Videnska 1083, Prague, 142 20, Czech Republic.

Meritxell Alberich-Jorda (M)

Department of Hemato-Oncology, Institute of Molecular Genetics of the ASCR, Videnska 1083, Prague 142 20, Prague 4, Czech Republic. alberich@img.cas.cz.

Classifications MeSH